Subscribe
ugisrigba
Ugis Rigba / Shutterstock.com
28 May 2020Big PharmaRory O'Neill

Report slams big pharma influence in EU-funded project

A  new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative (IMI) as favouring Big Pharma over small businesses, particularly when it comes to IP.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
EMA unveils fast-track drug shortage monitoring
8 April 2020   The EU’s drugs regulator has set up a fast-track system to monitor shortages during the COVID-19 pandemic.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
EMA unveils fast-track drug shortage monitoring
8 April 2020   The EU’s drugs regulator has set up a fast-track system to monitor shortages during the COVID-19 pandemic.

More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
EMA unveils fast-track drug shortage monitoring
8 April 2020   The EU’s drugs regulator has set up a fast-track system to monitor shortages during the COVID-19 pandemic.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?